Why this mid-cap biotech could be the dark-horse threat to Eli Lilly and Novo Nordisk The Motley Fool 5h The Motley Fool 5h Eli Lilly Pharma Ozempic All sources
STAT Plus: CMS recalculates Medicare Advantage star ratings again, adding more volatility to program STAT 4d STAT 4d Medicare Health Pharma All sources
How is Charles river laboratories’ stock performance compared to other health care stocks? Barchart 17h Barchart 17h Global Health Biotechnology Pharma All sources
Why CRISPR Therapeutics stock has been on a roller-coaster ride this year The Motley Fool 5d The Motley Fool 5d CRISPR/Gene Editing Biotechnology Global Stock Markets
Allen Hospital urology center launching advanced aquablation therapy for enlarged prostate Waterloo-Cedar Falls Courier, Iowa 7d Waterloo-Cedar Falls Courier, Iowa 7d Allen Hospital Iowa
Healthcare briefs: Parkland health earns certification from association for Clinical Oncology D Magazine 5d D Magazine 5d Dallas Texas Texas Business
Baxter Publishes 2025 Sustainability Report Highlighting Refreshed Strategy, Ongoing Commitment to Drive Meaningful Impact Baxter International (Press Release) 05:18
Why This Mid-Cap Biotech Could Be the Dark-Horse Threat to Eli Lilly and Novo Nordisk The Motley Fool 01:18
AbbVie's $10.9 Billion Apogee Deal Will Extend Its Immunology Dominance: Is It Time to Load Up on This Dividend King? The Motley Fool 23:46 Mon, 22 Jun